Navigation Links
First Patient Dosed with KX2-391 in Phase 1 Clinical Trial
Date:11/27/2007

BUFFALO, N.Y., Nov. 27 /PRNewswire/ -- Kinex Pharmaceuticals LLC, announced today that their drug KX2-391 (KX01) has begun Phase 1 human testing. The study is entitled "A combined rising single-dose (RSD) and rising multiple-dose (RMD) Phase 1 study to evaluate safety, tolerability and pharmacokinetics of KX2-391 in patients with advanced malignancies that are refractory to conventional therapies". The drug belongs to an emerging new family of targeted cancer treatments called protein kinase inhibitors.

Dosing has begun at Roswell Park Cancer Institute in Buffalo, N.Y., and will commence in the next several days at M.D. Anderson Cancer Center in Houston, Texas. The trial is expected to enroll 50 patients with advanced solid tumors and lymphoma and will evaluate safety, tolerability and pharmacokinetics. Exploratory biomarker studies will also be involved.

"What's remarkable about this compound is that, in preclinical testing, it has worked against every cancer and in every animal model," said David Hangauer, a University at Buffalo chemistry professor whose work was integral to the drug's creation. Hangauer is a co-founder of Kinex and serves as the Company's Senior Vice President of Research and Development. KX2-391 targets an important cell signaler called Src kinase, a protein linked to the rapid growth and spread of cancer cells. A potential advantage of Kinex's kinase inhibitor is that it disrupts Src at a site different from where other currently studied compounds are targeted, reducing the chance that patients will develop resistance to the new drug, Hangauer said.

"As we go further in the drug's development, and do broader testing, we get better and better data," said Allen Barnett, Chief Executive Officer of Kinex Pharmaceuticals. "We are extremely enthusiastic about the potential for KX2-391 because it represents a unique approach for the treatment of cancer. It is a first-in-class drug that has the potential to provide patients with a safe and effective treatment for a broad range of tumor types," said Barnett.

Contact: Lyn Dyster

Kinex Pharmaceuticals,

(716) 881-8984


'/>"/>
SOURCE Kinex Pharmaceuticals LLC
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
(Date:6/23/2016)... Research and Markets has announced the ... 2016 - Forecast to 2022" report to their offering. ... up to date financial data derived from varied research sources ... with potential impact on the market during the next five ... comprises of sub markets, regional and country level analysis. The ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 ... Tomorrow,s Leaders Scholarship is any indication, the future is ... online at www.diabetesscholars.org by the Diabetes Scholars ... in the way of academic and community service excellence. ... program since 2012, and continues to advocate for people ...
Breaking Medicine Technology:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... cutting edge technology to revolutionize the emergency ambulance transport experience for the millions ... aware of how Uber has disrupted the taxi industry through the use of ...
(Date:6/26/2016)... ... 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect ... videos a whole new perspective by using the title layers in ProSlice Levels ... , ProSlice Levels contains over 30 Different presets to choose from. FCPX ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... ... , ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter ... bar too high can result in disappointment, perhaps even self-loathing. However, those who set ... , Research from PsychTests.com reveals that behind the tendency to set low ...
Breaking Medicine News(10 mins):